Role of anabolic agents in colorectal carcinogenesis: Myths and realities (Review)

Roshan MH, Tambo A and Pace NP: The role of testosterone in colorectal carcinoma: Pathomechanisms and open questions. EPMA J. 7:222016. View Article : Google Scholar : PubMed/NCBI

Amos-Landgraf JM, Heijmans J, Wielenga MC, Dunkin E, Krentz KJ, Clipson L, Ederveen AG, Groothuis PG, Mosselman S, Muncan V, et al: Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones. Proc Natl Acad Sci USA. 111:16514–16519. 2014. View Article : Google Scholar : PubMed/NCBI

Docea AO, Goumenou M, Calina D, Arsene AL, Dragoi CM, Gofita E, Pisoschi CG, Zlatian O, Stivaktakis PD, Nikolouzakis TK, et al: Adverse and hormetic effects in rats exposed for 12 months to low dose mixture of 13 chemicals: RLRS part III. Toxicol Lett. 310:70–91. 2019. View Article : Google Scholar : PubMed/NCBI

Tsatsakis AM, Docea AO, Calina D, Buga AM, Zlatian O, Gutnikov S, Kostoff RN and Aschner M: Hormetic Neurobehavioral effects of low dose toxic chemical mixtures in real-life risk simulation (RLRS) in rats. Food Chem Toxicol. 125:141–149. 2019. View Article : Google Scholar : PubMed/NCBI

Tsatsakis AM, Kouretas D, Tzatzarakis MN, Stivaktakis P, Tsarouhas K, Golokhvast KS, Rakitskii VN, Tutelyan VA, Hernandez AF, Rezaee R, et al: Simulating real-life exposures to uncover possible risks to human health: A proposed consensus for a novel methodological approach. Hum Exp Toxicol. 36:554–564. 2017. View Article : Google Scholar : PubMed/NCBI

Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI

Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell. 87:159–170. 1996. View Article : Google Scholar : PubMed/NCBI

Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI

Nikolouzakis TK, Vassilopoulou L, Fragkiadaki P, Mariolis Sapsakos T, Papadakis GZ, Spandidos DA, Tsatsakis AM and Tsiaoussis J: Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review). Oncol Rep. 39:2455–2472. 2018.PubMed/NCBI

Terzic J, Grivennikov S, Karin E and Karin M: Inflammation and colon cancer. Gastroenterology. 138:2101–2114.e5. 2010. View Article : Google Scholar : PubMed/NCBI

Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF and Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 118:285–296. 2004. View Article : Google Scholar : PubMed/NCBI

Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, et al: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 15:103–113. 2009. View Article : Google Scholar : PubMed/NCBI

Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, et al Women's Health Initiative Investigators, : Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 350:991–1004. 2004. View Article : Google Scholar : PubMed/NCBI

Tsoukalas D, Fragkiadaki P, Docea AO, Alegakis AK, Sarandi E, Thanasoula M, Spandidos DA, Tsatsakis A, Razgonova MP and Calina D: Discovery of potent telomerase activators: Unfolding new therapeutic and anti-aging perspectives. Mol Med Rep. 20:3701–3708. 2019.PubMed/NCBI

Tsatsakis AM, Docea AO and Tsitsimpikou C: New challenges in risk assessment of chemicals when simulating real exposure scenarios; simultaneous multi-chemicals' low dose exposure. Food Chem Toxicol. 96:174–176. 2016. View Article : Google Scholar : PubMed/NCBI

Potter JD and McMichael AJ: Large bowel cancer in women in relation to reproductive and hormonal factors: A case-control study. J Natl Cancer Inst. 71:703–709. 1983.PubMed/NCBI

McMichael AJ and Potter JD: Reproduction, endogenous and exogenous sex hormones, and colon cancer: A review and hypothesis. J Natl Cancer Inst. 65:1201–1207. 1980.PubMed/NCBI

Young JL Jr, Asire AJ and Polalack ES: SEER Program: Cancer incidence and mortality in the United States: 1973–1976. US Department of Health, Education, and Welfare, NCI. 671978.

Burbank F: Patterns in cancer mortality in the United States: 1950–1967. Natl Cancer Inst Monogr. 71:1–594. 1971.PubMed/NCBI

Haenszel W and Correa P: Cancer of the colon and rectum and adenomatous polyps. A review of epidemiologic findings. Cancer. 28:14–24. 1971. View Article : Google Scholar : PubMed/NCBI

Howell MA: The association between colorectal cancer and breast cancer. J Chronic Dis. 29:243–261. 1976. View Article : Google Scholar : PubMed/NCBI

Izbicki JR, Wambach G, Hamilton SR, Harnisch E, Hogenschurz R, Izbicki W and Kusche J: Androgen receptors in experimentally induced colon carcinogenesis. J Cancer Res Clin Oncol. 112:39–46. 1986. View Article : Google Scholar : PubMed/NCBI

Nikolouzakis TK, Stivaktakis PD, Apalaki P, Kalliantasi K, Sapsakos TM, Spandidos DA, Tsatsakis A, Souglakos J and Tsiaoussis J: Effect of systemic treatment on the micronuclei frequency in the peripheral blood of patients with metastatic colorectal cancer. Oncol Lett. 17:2703–2712. 2019.PubMed/NCBI

Qiu S, Jiang C and Zhou L: Physical activity and mortality in patients with colorectal cancer: a meta-analysis of prospective cohort studies. Eur J Cancer Prev. April 5–2019. View Article : Google Scholar : PubMed/NCBI

Gabrielsen JS, Najari BB, Alukal JP and Eisenberg ML: Trends in Testosterone Prescription and Public Health Concerns. Urol Clin North Am. 43:261–271. 2016. View Article : Google Scholar : PubMed/NCBI

Georgiadis N, Tsarouhas K, Tsitsimpikou C, Vardavas A, Rezaee R, Germanakis I, Tsatsakis A, Stagos D and Kouretas D: Pesticides and cardiotoxicity. Where do we stand? Toxicol Appl Pharmacol. 353:1–14. 2018. View Article : Google Scholar : PubMed/NCBI

Margina D, Nițulescu G, Ungurianu A, Mesnage R, Goumenou M, Sarigiannis DA, Aschner M, Spandidos DA, Renieri EA, Hernández AF and Tsatsakis A: Overview of the effects of chemical mixtures with endocrine disrupting activity in the context of real life risk simulation (RLRS): an integrative approach (Review). World Acad Sci J (In press).

Veremchuk LV, Tsarouhas K, Vitkina TI, Mineeva EE, Gvozdenko TA, Antonyuk MV, Rakitskii VN, Sidletskaya KA, Tsatsakis AM and Golokhvast KS: Impact evaluation of environmental factors on respiratory function of asthma patients living in urban territory. Environ Pollut. 235:489–496. 2018. View Article : Google Scholar : PubMed/NCBI

Zafiropoulos A, Tsarouhas K, Tsitsimpikou C, Fragkiadaki P, Germanakis I, Tsardi M, Maravgakis G, Goutzourelas N, Vasilaki F, Kouretas D, et al: Cardiotoxicity in rabbits after a low-level exposure to diazinon, propoxur, and chlorpyrifos. Hum Exp Toxicol. 33:1241–1252. 2014. View Article : Google Scholar : PubMed/NCBI

Tsatsakis A, Docea AO, Constantin C, Calina D, Zlatian O, Nikolouzakis TK, Stivaktakis PD, Kalogeraki A, Liesivuori J, Tzanakakis G, et al: Genotoxic, cytotoxic, and cytopathological effects in rats exposed for 18 months to a mixture of 13 chemicals in doses below NOAEL levels. Toxicol Lett. Sep 12–2019.(Epub ahead of print). View Article : Google Scholar :

Ozcagli E, Kara M, Kotil T, Fragkiadaki P, Tzatzarakis MN, Tsitsimpikou C, Stivaktakis PD, Tsoukalas D, Spandidos DA, Tsatsakis AM, et al: Stanozolol administration combined with exercise leads to decreased telomerase activity possibly associated with liver aging. Int J Mol Med. 42:405–413. 2018.PubMed/NCBI

Kadıoğlu E, Taçoy G, Özçağlı E, Okyay K, Akboğa MK, Çengel A and Şardaş S: The role of oxidative DNA damage and GSTM1, GSTT1, and hOGG1 gene polymorphisms in coronary artery disease risk. Anatol J Cardiol. 16:931–938. 2016.PubMed/NCBI

McClendon JE, Appleby D, Claudon DB, Donegan WL and DeCosse JJ: Colonic neoplasms: Tissue estrogen receptor and carcinoembryonic antigen. Arch Surg. 112:240–241. 1977. View Article : Google Scholar : PubMed/NCBI

Alford TC, Do HM, Geelhoed GW, Tsangaris NT and Lippman ME: Steroid hormone receptors in human colon cancers. Cancer. 43:980–984. 1979. View Article : Google Scholar : PubMed/NCBI

Sica V, Contieri E, Nola E, Bova R, Papaleo G and Puca GA: Estrogen and progesterone binding proteins in human colorectal cancer. A preliminary characterization of estradiol receptor. Tumori. 67:307–314. 1981. View Article : Google Scholar : PubMed/NCBI

Odagiri E, Jibiki K, Demura R, Shinozaki H, Nakamura S, Demura H and Suzuki H: Steroid receptors and the distribution of IR-carcinoembryonic antigen in colonic cancer. Dis Colon Rectum. 27:787–791. 1984. View Article : Google Scholar : PubMed/NCBI

Jacobson HL: Present status of steroid hormone receptor in large bowel cancer. Prog Cancer Res Ther. 29:3671984.

Izbicki JR, Schmitz R, Hoppen HO, Izbicki W and Troidl H: Effects of steroid hormone therapy on primarily xenotransplanted human colorectal adenocarcinomas. J Cancer Res Clin Oncol. 108:345–350. 1984. View Article : Google Scholar : PubMed/NCBI

Wobbes T, Beex LVAM and Koenders AMJ: Estrogen and progestin receptors in colonic cancer? Dis Colon Rectum. 27:591–592. 1984. View Article : Google Scholar : PubMed/NCBI

Bucci L, Salfi R, Meraviglia F and Delric G: Hormonal receptors in colorectal cancers (abstract). Second European Conference on Clinical Oncology and Cancer Nursing. 8:41–98. 1983.

Handelsman DJ: Androgen Physiology, Pharmacology and AbuseEndotext [Internet]. Feingold KR, Anawalt B, Boyce A, et al: MDText.com, Inc.; South Dartmouth, MA: 2000

Hiort O, Holterhus PM and Nitsche EM: Physiology and pathophysiology of androgen action. Baillieres Clin Endocrinol Metab. 12:115–132. 1998. View Article : Google Scholar : PubMed/NCBI

Guyton AC and Hall JE: Textbook of medical physiology11th. Elsevier Saunders; Philladelphia, PA: 2006

Brenu EW, McNaughton L and Marshall-Gradisnik SM: Is there a potential immune dysfunction with anabolic androgenic steroid use?: A review. Mini Rev Med Chem. 11:438–445. 2011. View Article : Google Scholar : PubMed/NCBI

Tsarouhas K, Kioukia-Fougia N, Papalexis P, Tsatsakis A, Kouretas D, Bacopoulou F and Tsitsimpikou C: Use of nutritional supplements contaminated with banned doping substances by recreational adolescent athletes in Athens, Greece. Food Chem Toxicol. 115:447–450. 2018. View Article : Google Scholar : PubMed/NCBI

Tsitsimpikou C, Chrisostomou N, Papalexis P, Tsarouhas K, Tsatsakis A and Jamurtas A: The use of nutritional supplements among recreational athletes in Athens, Greece. Int J Sport Nutr Exerc Metab. 21:377–384. 2011. View Article : Google Scholar : PubMed/NCBI

Vasilaki F, Tsitsimpikou C, Tsarouhas K, Germanakis I, Tzardi M, Kavvalakis M, Ozcagli E, Kouretas D and Tsatsakis AM: Cardiotoxicity in rabbits after long-term nandrolone decanoate administration. Toxicol Lett. 241:143–151. 2016. View Article : Google Scholar : PubMed/NCBI

Baggish AL, Weiner RB, Kanayama G, Hudson JI, Picard MH, Hutter AM Jr and Pope HG Jr: Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail. 3:472–476. 2010. View Article : Google Scholar : PubMed/NCBI

Tsitsimpikou C, Tsarouhas K, Spandidos DA and Tsatsakis AM: Detection of stanozolol in the urine of athletes at a pg level: The possibility of passive exposure. Biomed Rep. 5:665–666. 2016. View Article : Google Scholar : PubMed/NCBI

Sattler FR, Jaque SV, Schroeder ET, Olson C, Dube MP, Martinez C, Briggs W, Horton R and Azen S: Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. J Clin Endocrinol Metab. 84:1268–1276. 1999. View Article : Google Scholar : PubMed/NCBI

Santos MA, Oliveira CV and Silva AS: Adverse cardiovascular effects from the use of anabolic-androgenic steroids as ergogenic resources. Subst Use Misuse. 49:1132–1137. 2014. View Article : Google Scholar : PubMed/NCBI

Bonetti A, Tirelli F, Catapano A, Dazzi D, Dei Cas A, Solito F, Ceda G, Reverberi C, Monica C, Pipitone S, et al: Side effects of anabolic androgenic steroids abuse. Int J Sports Med. 29:679–687. 2008. View Article : Google Scholar : PubMed/NCBI

Gould DC and Petty R: The male menopause: does it exist? For: Some men need investigation and testosterone treatment. West J Med. 173:76–78. 2000. View Article : Google Scholar : PubMed/NCBI

Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E and Shahinian VB: Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst. 102:1760–1770. 2010. View Article : Google Scholar : PubMed/NCBI

Izbicki JR, Schmitz R, Kamran D and Izbicki W: Androgens as promoters of colon carcinogenesis. Cancer Detect Prev. 6:355–362. 1983.PubMed/NCBI

Mehta RG, Fricks CM and Moon RC: Androgen receptors in chemically-induced colon carcinogenesis. Cancer. 45 (Suppl):1085–1089. 1980. View Article : Google Scholar : PubMed/NCBI

Moon RC and Fricks CM: Influence of gonadal hormones and age on 1,2-dimethylhydrazine-induced colon carcinogenesis. Cancer. 40 (Suppl):2502–2508. 1977. View Article : Google Scholar : PubMed/NCBI

Hyde Z, Flicker L, McCaul KA, Almeida OP, Hankey GJ, Chubb SA and Yeap BB: Associations between testosterone levels and incident prostate, lung, and colorectal cancer. A population-based study. Cancer Epidemiol Biomarkers Prev. 21:1319–1329. 2012. View Article : Google Scholar : PubMed/NCBI

Orsted DD, Nordestgaard BG and Bojesen SE: Plasma testosterone in the general population, cancer prognosis and cancer risk: A prospective cohort study. Ann Oncol. 25:712–718. 2014. View Article : Google Scholar : PubMed/NCBI

Koliarakis I, Psaroulaki A, Nikolouzakis TK, Kokkinakis M, Sgantzos MN, Goulielmos G, Androutsopoulos VP, Tsatsakis A and Tsiaoussis J: Intestinal microbiota and colorectal cancer: a new aspect of research. J BUON. 23:1216–1234. 2018.PubMed/NCBI

Alberg AJ, Gordon GB, Hoffman SC, Comstock GW and Helzlsouer KJ: Serum dehydroepiandrosterone and dehydroepiandrosterone sulfate and the subsequent risk of developing colon cancer. Cancer Epidemiol Biomarkers Prev. 9:517–521. 2000.PubMed/NCBI

Anagnostopoulou V, Pediaditakis I, Alkahtani S, Alarifi SA, Schmidt EM, Lang F, Gravanis A, Charalampopoulos I and Stournaras C: Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: The role of nerve growth factor (NGF) receptors. Endocrinology. 154:2446–2456. 2013. View Article : Google Scholar : PubMed/NCBI

Ferro P, Catalano MG, Raineri M, Reato G, dell'Eva R, Risio M, Foà R, Fortunati N and Pfeffer U: Somatic alterations of the androgen receptor CAG repeat in human colon cancer delineate a novel mutation pathway independent of microsatellite instability. Cancer Genet Cytogenet. 123:35–40. 2000. View Article : Google Scholar : PubMed/NCBI

Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD, Caan BJ and Samowitz W: Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev. 14:2936–2942. 2005. View Article : Google Scholar : PubMed/NCBI

Hoque A, Albanes D, Lippman SM, Spitz MR, Taylor PR, Klein EA, Thompson IM, Goodman P, Stanford JL, Crowley JJ, et al: Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control. 12:627–633. 2001. View Article : Google Scholar : PubMed/NCBI

Krithivas K, Yurgalevitch SM, Mohr BA, Wilcox CJ, Batter SJ, Brown M, Longcope C, McKinlay JB and Kantoff PW: Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J Endocrinol. 162:137–142. 1999. View Article : Google Scholar : PubMed/NCBI

Ding D, Xu L, Menon M, Reddy GP and Barrack ER: Effect of a short CAG (glutamine) repeat on human androgen receptor function. Prostate. 58:23–32. 2004. View Article : Google Scholar : PubMed/NCBI

Westberg L, Baghaei F, Rosmond R, Hellstrand M, Landén M, Jansson M, Holm G, Björntorp P and Eriksson E: Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metab. 86:2562–2568. 2001. View Article : Google Scholar : PubMed/NCBI

Rudolph A, Shi H, Försti A, Hoffmeister M, Sainz J, Jansen L, Hemminki K, Brenner H and Chang-Claude J: Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: Results from a German population-based case-control study. BMC Cancer. 14:8172014. View Article : Google Scholar : PubMed/NCBI

Bonin A, Bellemain E, Bronken Eidesen P, Pompanon F, Brochmann C and Taberlet P: How to track and assess genotyping errors in population genetics studies. Mol Ecol. 13:3261–3273. 2004. View Article : Google Scholar : PubMed/NCBI

Pompanon F, Bonin A, Bellemain E and Taberlet P: Genotyping errors: Causes, consequences and solutions. Nat Rev Genet. 6:847–859. 2005. View Article : Google Scholar : PubMed/NCBI

Huang R, Wang G, Song Y, Wang F, Zhu B, Tang Q, Liu Z, Chen Y, Zhang Q, Muhammad S, et al: Polymorphic CAG Repeat and Protein Expression of Androgen Receptor Gene in Colorectal Cancer. Mol Cancer Ther. 14:1066–1074. 2015. View Article : Google Scholar : PubMed/NCBI

Chamberlain NL, Driver ED and Miesfeld RL: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22:3181–3186. 1994. View Article : Google Scholar : PubMed/NCBI

Choong CS, Kemppainen JA, Zhou ZX and Wilson EM: Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol Endocrinol. 10:1527–1535. 1996. View Article : Google Scholar : PubMed/NCBI

Ferro P, Catalano MG, Dell'Eva R, Fortunati N and Pfeffer U: The androgen receptor CAG repeat: A modifier of carcinogenesis? Mol Cell Endocrinol. 193:109–120. 2002. View Article : Google Scholar : PubMed/NCBI

Catalano MG, Pfeffer U, Raineri M, Ferro P, Curto A, Capuzzi P, Corno F, Berta L and Fortunati N: Altered expression of androgen-receptor isoforms in human colon-cancer tissues. Int J Cancer. 86:325–330. 2000. View Article : Google Scholar : PubMed/NCBI

Gu S, Papadopoulou N, Nasir O, Föller M, Alevizopoulos K, Lang F and Stournaras C: Activation of membrane androgen receptors in colon cancer inhibits the prosurvival signals Akt/bad in vitro and in vivo and blocks migration via vinculin/actin signaling. Mol Med. 17:48–58. 2011. View Article : Google Scholar : PubMed/NCBI

Gu S, Papadopoulou N, Gehring EM, Nasir O, Dimas K, Bhavsar SK, Föller M, Alevizopoulos K, Lang F and Stournaras C: Functional membrane androgen receptors in colon tumors trigger pro-apoptotic responses in vitro and reduce drastically tumor incidence in vivo. Mol Cancer. 8:1142009. View Article : Google Scholar : PubMed/NCBI

Chesire DR and Isaacs WB: Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. Oncogene. 21:8453–8469. 2002. View Article : Google Scholar : PubMed/NCBI

Yoshioka T, Nishikawa Y, Ito R, Kawamata M, Doi Y, Yamamoto Y, Yoshida M, Omori Y, Kotanagi H, Masuko T, et al: Significance of integrin αvβ5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin. Cancer Sci. 101:2011–2018. 2010. View Article : Google Scholar : PubMed/NCBI

Holgren C, Dougherty U, Edwin F, Cerasi D, Taylor I, Fichera A, Joseph L, Bissonnette M and Khare S: Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: Sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene. 29:5241–5253. 2010. View Article : Google Scholar : PubMed/NCBI

Huynh N, Liu KH, Baldwin GS and He H: P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways. Biochim Biophys Acta. 1803:1106–1113. 2010. View Article : Google Scholar : PubMed/NCBI

Teyssier C, Ou CY, Khetchoumian K, Losson R and Stallcup MR: Transcriptional intermediary factor 1alpha mediates physical interaction and functional synergy between the coactivator-associated arginine methyltransferase 1 and glucocorticoid receptor-interacting protein 1 nuclear receptor coactivators. Mol Endocrinol. 20:1276–1286. 2006. View Article : Google Scholar : PubMed/NCBI

Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad DW and Stallcup MR: Regulation of transcription by a protein methyltransferase. Science. 284:2174–2177. 1999. View Article : Google Scholar : PubMed/NCBI

Koh SS, Li H, Lee YH, Widelitz RB, Chuong CM and Stallcup MR: Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and beta-catenin with two different classes of DNA-binding transcriptional activators. J Biol Chem. 277:26031–26035. 2002. View Article : Google Scholar : PubMed/NCBI

El Messaoudi S, Fabbrizio E, Rodriguez C, Chuchana P, Fauquier L, Cheng D, Theillet C, Vandel L, Bedford MT and Sardet C: Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc Natl Acad Sci USA. 103:13351–13356. 2006. View Article : Google Scholar : PubMed/NCBI

Kim YR, Lee BK, Park RY, Nguyen NT, Bae JA, Kwon DD and Jung C: Differential CARM1 expression in prostate and colorectal cancers. BMC Cancer. 10:1972010. View Article : Google Scholar : PubMed/NCBI

Ilboudo S, Fouche E, Rizzati V, Toé AM, Gamet-Payrastre L and Guissou PI: In vitro impact of five pesticides alone or in combination on human intestinal cell line Caco-2. Toxicol Rep. 1:474–489. 2014. View Article : Google Scholar : PubMed/NCBI

Carroll RE, Goodlad RA, Poole AJ, Tyner AL, Robey RB, Swanson SM and Unterman TG: Reduced susceptibility to azoxymethane-induced aberrant crypt foci formation and colon cancer in growth hormone deficient rats. Growth Horm IGF Res. 19:447–456. 2009. View Article : Google Scholar : PubMed/NCBI

Chuang KH, Altuwaijri S, Li G, Lai JJ, Chu CY, Lai KP, Lin HY, Hsu JW, Keng P, Wu MC, et al: Neutropenia with impaired host defense against microbial infection in mice lacking androgen receptor. J Exp Med. 206:1181–1199. 2009. View Article : Google Scholar : PubMed/NCBI

Mårin P, Krotkiewski M and Björntorp P: Androgen treatment of middle-aged, obese men: Effects on metabolism, muscle and adipose tissues. Eur J Med. 1:329–336. 1992.PubMed/NCBI

Lin JH and Giovannucci E: Sex hormones and colorectal cancer: What have we learned so far? J Natl Cancer Inst. 102:1746–1747. 2010. View Article : Google Scholar : PubMed/NCBI

Thevis M and Schänzer W: Synthetic anabolic agents: Steroids and nonsteroidal selective androgen receptor modulatorsDoping in Sports: Biochemical Principles, Effects and Analysis. Handbook of Experimental Pharmacology. Thieme D and Hemmersbach P: 195. Springer; Berlin, Heidelberg: pp. 99–126. 2010, View Article : Google Scholar

Joseph JF and Parr MK: Synthetic androgens as designer supplements. Curr Neuropharmacol. 13:89–100. 2015. View Article : Google Scholar : PubMed/NCBI

Watanabe S and Kobayashi Y: Exogenous hormones and human cancer. Jpn J Clin Oncol. 23:1–13. 1993.PubMed/NCBI

Rosner F and Khan MT: Renal cell carcinoma following prolonged testosterone therapy. Arch Intern Med. 152:426–429. 1992. View Article : Google Scholar : PubMed/NCBI

Martorana G, Concetti S, Manferrari F and Creti S: Anabolic steroid abuse and renal cell carcinoma. J Urol. 162:2089. 1999. View Article : Google Scholar : PubMed/NCBI

Bryden AAG, Rothwell PJN and O'Reilly PH: Anabolic steroid abuse and renal-cell carcinoma. Lancet. 346:1306–1307. 1995. View Article : Google Scholar : PubMed/NCBI

Zahm SH and Fraumeni JF Jr: The epidemiology of soft tissue sarcoma. Semin Oncol. 24:504–514. 1997.PubMed/NCBI

Nourbakhsh M, Golestani A, Zahrai M, Modarressi MH, Malekpour Z and Karami-Tehrani F: Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells. Mol Cell Endocrinol. 330:10–16. 2010. View Article : Google Scholar : PubMed/NCBI

McKeown-Eyssen G: Epidemiology of colorectal cancer revisited: Are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev. 3:687–695. 1994.PubMed/NCBI

Bronson FH and Matherne CM: Exposure to anabolic-androgenic steroids shortens life span of male mice. Med Sci Sports Exerc. 29:615–619. 1997. View Article : Google Scholar : PubMed/NCBI

Froehner M, Fischer R, Leike S, Hakenberg OW, Noack B and Wirth MP: Intratesticular leiomyosarcoma in a young man after high dose doping with oral-turinabol: A case report. Cancer. 86:1571–1575. 1999. View Article : Google Scholar : PubMed/NCBI

Chacon A and Monga M: Medical management of benign prostatic hyperplasia. Geriatr Nephrol Urol. 9:39–48. 1999. View Article : Google Scholar : PubMed/NCBI

Dimitriadis G, Mitrou P, Lambadiari V, Maratou E and Raptis SA: Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract. 93 (Suppl 1):S52–S59. 2011. View Article : Google Scholar : PubMed/NCBI

Giovannucci E and Michaud D: The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 132:2208–2225. 2007. View Article : Google Scholar : PubMed/NCBI

Yang YX, Hennessy S and Lewis JD: Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 127:1044–1050. 2004. View Article : Google Scholar : PubMed/NCBI

Larsson SC, Orsini N, Brismar K and Wolk A: Diabetes mellitus and risk of bladder cancer: A meta-analysis. Diabetologia. 49:2819–2823. 2006. View Article : Google Scholar : PubMed/NCBI

Flood A, Mai V, Pfeiffer R, Kahle L, Remaley AT, Lanza E and Schatzkin A: Elevated serum concentrations of insulin and glucose increase risk of recurrent colorectal adenomas. Gastroenterology. 133:1423–1429. 2007. View Article : Google Scholar : PubMed/NCBI

Polednak AP: Comorbid diabetes mellitus and risk of death after diagnosis of colorectal cancer: A population-based study. Cancer Detect Prev. 30:466–472. 2006. View Article : Google Scholar : PubMed/NCBI

Jullumstrø E, Kollind M, Lydersen S and Edna TH: Diabetes mellitus and outcomes of colorectal cancer. Acta Oncol. 48:361–367. 2009. View Article : Google Scholar : PubMed/NCBI

Schoen RE, Weissfeld JL, Kuller LH, Thaete FL, Evans RW, Hayes RB and Rosen CJ: Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology. 129:464–475. 2005. View Article : Google Scholar : PubMed/NCBI

LeRoith D, Baserga R, Helman L and Roberts CT Jr: Insulin-like growth factors and cancer. Ann Intern Med. 122:54–59. 1995. View Article : Google Scholar : PubMed/NCBI

Sandhu MS, Dunger DB and Giovannucci EL: Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 94:972–980. 2002. View Article : Google Scholar : PubMed/NCBI

Siddle K: Signalling by insulin and IGF receptors: Supporting acts and new players. J Mol Endocrinol. 47:R1–R10. 2011. View Article : Google Scholar : PubMed/NCBI

Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A and McClain DA: Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J. 9:2409–2413. 1990. View Article : Google Scholar : PubMed/NCBI

Abbruzzese C, Diodoro MG, Sperduti I, Mileo AM, Pattaro G, De Salvo L, Cosimelli M, Perrotti N and Paggi MG: Detection of phosphorylated insulin receptor in colorectal adenoma and adenocarcinoma: Implications for prognosis and clinical outcome. J Cell Physiol. 230:562–567. 2015. View Article : Google Scholar : PubMed/NCBI

Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A and Vigneri R: Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 19:3278–3288. 1999. View Article : Google Scholar : PubMed/NCBI

Kosaki A and Webster NJ: Effect of dexamethasone on the alternative splicing of the insulin receptor mRNA and insulin action in HepG2 hepatoma cells. J Biol Chem. 268:21990–21996. 1993.PubMed/NCBI

Heckl SM, Pellinghaus M, Krüger S, Bosselmann C, Wilhelm F, Behrens HM, Schreiber S and Röcken C: Epithelial insulin receptor expression-prognostic relevance in colorectal cancer. Oncotarget. 9:37497–37508. 2018. View Article : Google Scholar : PubMed/NCBI

Morcavallo A, Genua M, Palummo A, Kletvikova E, Jiracek J, Brzozowski AM, Iozzo RV, Belfiore A and Morrione A: Insulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of insulin receptor isoform A. J Biol Chem. 287:11422–11436. 2012. View Article : Google Scholar : PubMed/NCBI

Wang X, Häring MF, Rathjen T, Lockhart SM, Sørensen D, Ussar S, Rasmussen LM, Bertagnolli MM, Kahn CR and Rask-Madsen C: Insulin resistance in vascular endothelial cells promotes intestinal tumour formation. Oncogene. 36:4987–4996. 2017. View Article : Google Scholar : PubMed/NCBI

Laakso M, Edelman SV, Brechtel G and Baron AD: Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes. 41:1076–1083. 1992. View Article : Google Scholar : PubMed/NCBI

Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G and Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 97:2601–2610. 1996. View Article : Google Scholar : PubMed/NCBI

Rask-Madsen C, Ihlemann N, Krarup T, Christiansen E, Kober L, Nervil Kistorp C and Torp-Pedersen C: Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes. 50:2611–2618. 2001. View Article : Google Scholar : PubMed/NCBI

Tabit CE, Shenouda SM, Holbrook M, Fetterman JL, Kiani S, Frame AA, Kluge MA, Held A, Dohadwala MM, Gokce N, et al: Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation. 127:86–95. 2013. View Article : Google Scholar : PubMed/NCBI

Simpson RJ, Lim JW, Moritz RL and Mathivanan S: Exosomes: Proteomic insights and diagnostic potential. Expert Rev Proteomics. 6:267–283. 2009. View Article : Google Scholar : PubMed/NCBI

Gangoda L and Mathivanan S: Cortactin enhances exosome secretion without altering cargo. J Cell Biol. 214:129–131. 2016. View Article : Google Scholar : PubMed/NCBI

Gangoda L, Boukouris S, Liem M, Kalra H and Mathivanan S: Extracellular vesicles including exosomes are mediators of signal transduction: Are they protective or pathogenic? Proteomics. 15:260–271. 2015. View Article : Google Scholar : PubMed/NCBI

Silantyev AS, Falzone L, Libra M, Gurina OI, Kardashova KS, Nikolouzakis TK, Nosyrev AE, Sutton CW, Mitsias PD and Tsatsakis A: Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics. Cells. 8:82019. View Article : Google Scholar

Taniguchi CM, Emanuelli B and Kahn CR: Critical nodes in signalling pathways: Insights into insulin action. Nat Rev Mol Cell Biol. 7:85–96. 2006. View Article : Google Scholar : PubMed/NCBI

Huang XF and Chen JZ: Obesity, the PI3K/Akt signal pathway and colon cancer. Obes Rev. 10:610–616. 2009. View Article : Google Scholar : PubMed/NCBI

Matsuzaki H, Daitoku H, Hatta M, Tanaka K and Fukamizu A: Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci USA. 100:11285–11290. 2003. View Article : Google Scholar : PubMed/NCBI

Liem M, Ang CS and Mathivanan S: Insulin Mediated Activation of PI3K/Akt Signalling Pathway Modifies the Proteomic Cargo of Extracellular Vesicles. Proteomics. 17:172017. View Article : Google Scholar

Baserga R: The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res. 55:249–252. 1995.PubMed/NCBI

Párrizas M and LeRoith D: Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology. 138:1355–1358. 1997. View Article : Google Scholar : PubMed/NCBI

Wang L, Ma W, Markovich R, Lee WL and Wang PH: Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells. Endocrinology. 139:1354–1360. 1998. View Article : Google Scholar : PubMed/NCBI

Remacle-Bonnet MM, Garrouste FL, Heller S, André F, Marvaldi JL and Pommier GJ: Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res. 60:2007–2017. 2000.PubMed/NCBI

Liu B, Fang M, Lu Y, Mendelsohn J and Fan Z: Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene. 20:1913–1922. 2001. View Article : Google Scholar : PubMed/NCBI

Ryan PD and Goss PE: The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist. 13:16–24. 2008. View Article : Google Scholar : PubMed/NCBI

Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer. 12:159–169. 2012. View Article : Google Scholar : PubMed/NCBI

Islam MA, Hooiveld GJEJ, van den Berg JHJ, van der Velpen V, Murk AJ, Rietjens IMCM and van Leeuwen FXR: Soy supplementation: Impact on gene expression in different tissues of ovariectomized rats and evaluation of the rat model to predict (post)menopausal health effect. Toxicol Rep. 5:1087–1097. 2018. View Article : Google Scholar : PubMed/NCBI

Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH and Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 91:620–625. 1999. View Article : Google Scholar : PubMed/NCBI

Lahm H, Suardet L, Laurent PL, Fischer JR, Ceyhan A, Givel JC and Odartchenko N: Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor alpha. Br J Cancer. 65:341–346. 1992. View Article : Google Scholar : PubMed/NCBI

Guo YS, Narayan S, Yallampalli C and Singh P: Characterization of insulinlike growth factor I receptors in human colon cancer. Gastroenterology. 102:1101–1108. 1992. View Article : Google Scholar : PubMed/NCBI

Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E and Raz I: Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut. 44:704–708. 1999. View Article : Google Scholar : PubMed/NCBI

Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, Karl RC and Coppola D: Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol. 30:1128–1133. 1999. View Article : Google Scholar : PubMed/NCBI

Lee J, Jain A, Kim P, Lee T, Kuller A, Princen F, In-GuDo, Kim SH, Park JO, Park YS, et al: Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. PLoS One. 9:e1035512014. View Article : Google Scholar : PubMed/NCBI

Soubry A, Il'yasova D, Sedjo R, Wang F, Byers T, Rosen C, Yashin A, Ukraintseva S, Haffner S and D'Agostino R Jr: Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps. Int J Cancer. 131:512–517. 2012. View Article : Google Scholar : PubMed/NCBI

Ollberding NJ, Cheng I, Wilkens LR, Henderson BE, Pollak MN, Kolonel LN and Le Marchand L: Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the risk of colorectal cancer: The Multiethnic Cohort study. Cancer Epidemiol Biomarkers Prev. 21:810–820. 2012. View Article : Google Scholar : PubMed/NCBI

Giovannucci E: Insulin, insulin-like growth factors and colon cancer: A review of the evidence. J Nutr. 131 (Suppl):3109S–3120S. 2001. View Article : Google Scholar : PubMed/NCBI

Shiratsuchi I, Akagi Y, Kawahara A, Kinugasa T, Romeo K, Yoshida T, Ryu Y, Gotanda Y, Kage M and Shirouzu K: Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer. Anticancer Res. 31:2541–2545. 2011.PubMed/NCBI

Peters G, Gongoll S, Langner C, Mengel M, Piso P, Klempnauer J, Rüschoff J, Kreipe H and von Wasielewski R: IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 443:139–145. 2003. View Article : Google Scholar : PubMed/NCBI

Furlanetto RW, Harwell SE and Frick KK: Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. Mol Endocrinol. 8:510–517. 1994. View Article : Google Scholar : PubMed/NCBI

Sahin AA, Ro JY, Brown RW, Ordonez NG, Cleary KR, el-Naggar AK, Wilson P and Ayala AG: Assessment of Ki-67-derived tumor proliferative activity in colorectal adenocarcinomas. Mod Pathol. 7:17–22. 1994.PubMed/NCBI

Kubota Y, Petras RE, Easley KA, Bauer TW, Tubbs RR and Fazio VW: Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer. 70:2602–2609. 1992. View Article : Google Scholar : PubMed/NCBI

Cascinu S, Del Ferro E, Grianti C, Ligi M, Ghiselli R, Foglietti G, Saba V, Lungarotti F and Catalano G: Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients. Gastroenterology. 113:767–772. 1997. View Article : Google Scholar : PubMed/NCBI

Bowers LW, Rossi EL, O'Flanagan CH, deGraffenried LA and Hursting SD: The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link. Front Endocrinol (Lausanne). 6:772015. View Article : Google Scholar : PubMed/NCBI

Firth SM and Baxter RC: Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 23:824–854. 2002. View Article : Google Scholar : PubMed/NCBI

Liou JM, Shun CT, Liang JT, Chiu HM, Chen MJ, Chen CC, Wang HP, Wu MS and Lin JT: Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab. 95:1717–1725. 2010. View Article : Google Scholar : PubMed/NCBI

Jones JI and Clemmons DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev. 16:3–34. 1995. View Article : Google Scholar : PubMed/NCBI

Héron-Milhavet L and LeRoith D: Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem. 277:15600–15606. 2002. View Article : Google Scholar : PubMed/NCBI

Peretz S, Jensen R, Baserga R and Glazer PM: ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci USA. 98:1676–1681. 2001. View Article : Google Scholar : PubMed/NCBI

Huang F, Xu LA and Khambata-Ford S: Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer. Clin Cancer Res. 18:1156–1166. 2012. View Article : Google Scholar : PubMed/NCBI

Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE and Nicholson RI: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer. 11:793–814. 2004. View Article : Google Scholar : PubMed/NCBI

Albanell J and Baselga J: Unraveling resistance to trastuzumab (Herceptin): Insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst. 93:1830–1832. 2001. View Article : Google Scholar : PubMed/NCBI

Shen K, Cui D, Sun L, Lu Y, Han M and Liu J: Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression. J Cell Biochem. 113:2086–2097. 2012. View Article : Google Scholar : PubMed/NCBI

Warren RS, Yuan H, Matli MR, Ferrara N and Donner DB: Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. 271:29483–29488. 1996. View Article : Google Scholar : PubMed/NCBI

Akagi Y, Liu W, Zebrowski B, Xie K and Ellis LM: Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res. 58:4008–4014. 1998.PubMed/NCBI

Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z, Dan HC, Boulware D, Cheng JQ and Coppola D: Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res. 63:7708–7716. 2003.PubMed/NCBI

Zhang QY, Wang L, Song ZY and Qu XJ: Knockdown of type I insulin-like growth factor receptor inhibits human colorectal cancer cell growth and downstream PI3K/Akt, WNT/β-catenin signal pathways. Biomed Pharmacother. 73:12–18. 2015. View Article : Google Scholar : PubMed/NCBI

Nahor I, Abramovitch S, Engeland K and Werner H: The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Horm IGF Res. 15:388–396. 2005. View Article : Google Scholar : PubMed/NCBI

Ramocki NM, Wilkins HR, Magness ST, Simmons JG, Scull BP, Lee GH, McNaughton KK and Lund PK: Insulin receptor substrate-1 deficiency promotes apoptosis in the putative intestinal crypt stem cell region, limits Apcmin/+ tumors, and regulates Sox9. Endocrinology. 149:261–267. 2008. View Article : Google Scholar : PubMed/NCBI

Chan BT and Lee AV: Insulin receptor substrates (IRSs) and breast tumorigenesis. J Mammary Gland Biol Neoplasia. 13:415–422. 2008. View Article : Google Scholar : PubMed/NCBI

Esposito DL, Aru F, Lattanzio R, Morgano A, Abbondanza M, Malekzadeh R, Bishehsari F, Valanzano R, Russo A, Piantelli M, et al: The insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancer. PLoS One. 7:e361902012. View Article : Google Scholar : PubMed/NCBI

Day E, Poulogiannis G, McCaughan F, Mulholland S, Arends MJ, Ibrahim AE and Dear PH: IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer. Int J Exp Pathol. 94:203–211. 2013.PubMed/NCBI

Slattery ML, Samowitz W, Curtin K, Ma KN, Hoffman M, Caan B and Neuhausen S: Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev. 13:1206–1214. 2004.PubMed/NCBI

Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K, Levitzki A and Karin M: Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene. 35:2634–2644. 2016. View Article : Google Scholar : PubMed/NCBI

Krajewski W, Dzięgała M, Kołodziej A, Dembowski J and Zdrojowy R: Vitamin D and urological cancers. Cent European J Urol. 69:139–147. 2016.PubMed/NCBI

Lefkowitz ES and Garland CF: Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol. 23:1133–1136. 1994. View Article : Google Scholar : PubMed/NCBI

Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA and Van Leeuwen JP: Genetics and biology of vitamin D receptor polymorphisms. Gene. 338:143–156. 2004. View Article : Google Scholar : PubMed/NCBI

Boscoe FP and Schymura MJ: Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993–2002. BMC Cancer. 6:2642006. View Article : Google Scholar : PubMed/NCBI

Bishop JE, Collins ED, Okamura WH and Norman AW: Profile of ligand specificity of the vitamin D binding protein for 1 alpha,25-dihydroxyvitamin D3 and its analogs. J Bone Miner Res. 9:1277–1288. 1994. View Article : Google Scholar : PubMed/NCBI

Bikle D: Vitamin D: Production, Metabolism, and Mechanisms of ActionEndotext [Internet]. Feingold KR, Anawalt B, Boyce A, et al: MDText.com, Inc.; South Dartmouth, MA: 2000

Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW and Giovannucci EL: Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 13:1502–1508. 2004.PubMed/NCBI

Braun MM, Helzlsouer KJ, Hollis BW and Comstock GW: Colon cancer and serum vitamin D metabolite levels 10–17 years prior to diagnosis. Am J Epidemiol. 142:608–611. 1995. View Article : Google Scholar : PubMed/NCBI

Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M and Holick MF: Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol. 97:179–194. 2005. View Article : Google Scholar : PubMed/NCBI

Garland C, Shekelle RB, Barrett-Connor E, Criqui MH, Rossof AH and Paul O: Dietary vitamin D and calcium and risk of colorectal cancer: A 19-year prospective study in men. Lancet. 1:307–309. 1985. View Article : Google Scholar : PubMed/NCBI

Garland CF and Garland FC: Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol. 9:227–231. 1980. View Article : Google Scholar : PubMed/NCBI

Belleli A, Shany S, Levy J, Guberman R and Lamprecht SA: A protective role of 1,25-dihydroxyvitamin D3 in chemically induced rat colon carcinogenesis. Carcinogenesis. 13:2293–2298. 1992. View Article : Google Scholar : PubMed/NCBI

Comer PF, Clark TD and Glauert HP: Effect of dietary vitamin D3 (cholecalciferol) on colon carcinogenesis induced by 1,2-dimethylhydrazine in male Fischer 344 rats. Nutr Cancer. 19:113–124. 1993. View Article : Google Scholar : PubMed/NCBI

Thomas MG, Tebbutt S and Williamson RC: Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut. 33:1660–1663. 1992. View Article : Google Scholar : PubMed/NCBI

Brehier A and Thomasset M: Human colon cell line HT-29: Characterisation of 1,25-dihydroxyvitamin D3 receptor and induction of differentiation by the hormone. J Steroid Biochem. 29:265–270. 1988. View Article : Google Scholar : PubMed/NCBI

Cross HS, Farsoudi KH and Peterlik M: Growth inhibition of human colon adenocarcinoma-derived Caco-2 cells by 1,25-dihydroxyvitamin D3 and two synthetic analogs: Relation to in vitro hypercalcemic potential. Naunyn Schmiedebergs Arch Pharmacol. 347:105–110. 1993. View Article : Google Scholar : PubMed/NCBI

Vandewalle B, Adenis A, Hornez L, Revillion F and Lefebvre J: 1,25-dihydroxyvitamin D3 receptors in normal and malignant human colorectal tissues. Cancer Lett. 86:67–73. 1994. View Article : Google Scholar : PubMed/NCBI

Zhao X and Feldman D: Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. Endocrinology. 132:1808–1814. 1993. View Article : Google Scholar : PubMed/NCBI

Carlberg C and Dunlop TW: An integrated biological approach to nuclear receptor signaling in physiological control and disease. Crit Rev Eukaryot Gene Expr. 16:1–22. 2006. View Article : Google Scholar : PubMed/NCBI

Padi SK, Zhang Q, Rustum YM, Morrison C and Guo B: MicroRNA-627 mediates the epigenetic mechanisms of vitamin D to suppress proliferation of human colorectal cancer cells and growth of xenograft tumors in mice. Gastroenterology. 145:437–446. 2013. View Article : Google Scholar : PubMed/NCBI

Fernandez-Garcia NI, Palmer HG, Garcia M, Gonzalez-Martin A, del Rio M, Barettino D, Volpert O, Muñoz A and Jimenez B: 1alpha,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene. 24:6533–6544. 2005. View Article : Google Scholar : PubMed/NCBI

Pendás-Franco N, Aguilera O, Pereira F, González-Sancho JM and Muñoz A: Vitamin D and Wnt/β-catenin pathway in colon cancer: Role and regulation of DICKKOPF genes. Anticancer Res 28 (5A). 2613–2623. 2008.

Ylikomi T, Laaksi I, Lou YR, Martikainen P, Miettinen S, Pennanen P, Purmonen S, Syvälä H, Vienonen A and Tuohimaa P: Antiproliferative action of vitamin D. Vitam Horm. 64:357–406. 2002. View Article : Google Scholar : PubMed/NCBI

Taghizadeh F, Tang MJ and Tai IT: Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol Cancer Ther. 6:309–317. 2007. View Article : Google Scholar : PubMed/NCBI

Pálmer HG, Sánchez-Carbayo M, Ordóñez-Morán P, Larriba MJ, Cordón-Cardó C and Muñoz A: Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res. 63:7799–7806. 2003.PubMed/NCBI

Jensen SS, Madsen MW, Lukas J, Binderup L and Bartek J: Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 15:1370–1380. 2001. View Article : Google Scholar : PubMed/NCBI

Scaglione-Sewell BA, Bissonnette M, Skarosi S, Abraham C and Brasitus TA: A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: Roles of cyclin E, p21Waf1, and p27Kip1. Endocrinology. 141:3931–3939. 2000. View Article : Google Scholar : PubMed/NCBI

Liu W, Chen Y, Golan MA, Annunziata ML, Du J, Dougherty U, Kong J, Musch M, Huang Y, Pekow J, et al: Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest. 123:3983–3996. 2013. View Article : Google Scholar : PubMed/NCBI

Murillo G, Nagpal V, Tiwari N, Benya RV and Mehta RG: Actions of vitamin D are mediated by the TLR4 pathway in inflammation-induced colon cancer. J Steroid Biochem Mol Biol. 121:403–407. 2010. View Article : Google Scholar : PubMed/NCBI

Kim KE and Brasitus TA: The role of vitamin D in normal and pathologic processes in the colon. Curr Opin Gastroenterol. 17:72–77. 2001. View Article : Google Scholar : PubMed/NCBI

Revelli A, Massobrio M and Tesarik J: Nongenomic effects of 1α,25-dihydroxyvitamin D(3). Trends Endocrinol Metab. 9:419–427. 1998. View Article : Google Scholar : PubMed/NCBI

Norman AW, Song X, Zanello L, Bula C and Okamura WH: Rapid and genomic biological responses are mediated by different shapes of the agonist steroid hormone, 1α,25(OH)2vitamin D3. Steroids. 64:120–128. 1999. View Article : Google Scholar : PubMed/NCBI

Sitrin MD, Bissonnette M, Bolt MJ, Wali R, Khare S, Scaglione-Sewell B, Skarosi S and Brasitus TA: Rapid effects of 1,25(OH)2 vitamin D3 on signal transduction systems in colonic cells. Steroids. 64:137–142. 1999. View Article : Google Scholar : PubMed/NCBI

Nelson WJ and Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004. View Article : Google Scholar : PubMed/NCBI

Jeanes A, Gottardi CJ and Yap AS: Cadherins and cancer: How does cadherin dysfunction promote tumor progression? Oncogene. 27:6920–6929. 2008. View Article : Google Scholar : PubMed/NCBI

Rozen F, Yang XF, Huynh H and Pollak M: Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. J Natl Cancer Inst. 89:652–656. 1997. View Article : Google Scholar : PubMed/NCBI

Kaler P, Augenlicht L and Klampfer L: Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: A crosstalk interrupted by vitamin D3. Oncogene. 28:3892–3902. 2009. View Article : Google Scholar : PubMed/NCBI

Kaler P, Galea V, Augenlicht L and Klampfer L: Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells. PLoS One. 5:e117002010. View Article : Google Scholar : PubMed/NCBI

Chen A, Davis BH, Sitrin MD, Brasitus TA and Bissonnette M: Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3). Am J Physiol Gastrointest Liver Physiol. 283:G864–G874. 2002. View Article : Google Scholar : PubMed/NCBI

Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazono K and Kato S: Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science. 283:1317–1321. 1999. View Article : Google Scholar : PubMed/NCBI

Deeb KK, Trump DL and Johnson CS: Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer. 7:684–700. 2007. View Article : Google Scholar : PubMed/NCBI

Tong WM, Hofer H, Ellinger A, Peterlik M and Cross HS: Mechanism of antimitogenic action of vitamin D in human colon carcinoma cells: Relevance for suppression of epidermal growth factor-stimulated cell growth. Oncol Res. 11:77–84. 1999.PubMed/NCBI

Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y and Mabjeesh NJ: 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther. 6:1433–1439. 2007. View Article : Google Scholar : PubMed/NCBI

Harris DM and Go VL: Vitamin D and colon carcinogenesis. J Nutr. 134 (Suppl):3463S–3471S. 2004. View Article : Google Scholar : PubMed/NCBI

Lappe JM, Travers-Gustafson D, Davies KM, Recker RR and Heaney RP: Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr. 85:1586–1591. 2007. View Article : Google Scholar : PubMed/NCBI

Binder G, Wittekindt N and Ranke MB: Noonan Syndrome: Genetics and Responsiveness to Growth Hormone Therapy. Horm Res Paediatr. 67:45–49. 2007. View Article : Google Scholar

Campbell GS: Growth-hormone signal transduction. J Pediatr. 131:S42–S44. 1997. View Article : Google Scholar : PubMed/NCBI

Savage MO, Blum WF, Ranke MB, Postel-Vinay MC, Cotterill AM, Hall K, Chatelain PG, Preece MA and Rosenfeld RG: Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome). J Clin Endocrinol Metab. 77:1465–1471. 1993. View Article : Google Scholar : PubMed/NCBI

Gunawardane K, Hansen TK, Muller N, Christiansen JS and Jorgensen JOL: Normal Physiology of Growth Hormone in AdultsEndotext [Internet]. Feingold KR, Anawalt B and Boyce A: MDText.com, Inc.; South Dartmouth, MA: 2000

Slater MD and Murphy CR: Co-expression of interleukin-6 and human growth hormone in apparently normal prostate biopsies that ultimately progress to prostate cancer using low pH, high temperature antigen retrieval. J Mol Histol. 37:37–41. 2006. View Article : Google Scholar : PubMed/NCBI

Waters MJ and Conway-Campbell BL: The oncogenic potential of autocrine human growth hormone in breast cancer. Proc Natl Acad Sci USA. 101:14992–14993. 2004. View Article : Google Scholar : PubMed/NCBI

Brooks AJ and Waters MJ: The growth hormone receptor: Mechanism of activation and clinical implications. Nat Rev Endocrinol. 6:515–525. 2010. View Article : Google Scholar : PubMed/NCBI

Brown-Borg HM and Bartke A: GH and IGF1: Roles in energy metabolism of long-living GH mutant mice. J Gerontol A Biol Sci Med Sci. 67:652–660. 2012. View Article : Google Scholar : PubMed/NCBI

Chesnokova V, Zonis S, Zhou C, Recouvreux MV, Ben-Shlomo A, Araki T, Barrett R, Workman M, Wawrowsky K, Ljubimov VA, et al: Growth hormone is permissive for neoplastic colon growth. Proc Natl Acad Sci USA. 113:E3250–E3259. 2016. View Article : Google Scholar : PubMed/NCBI

Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 275:1787–1790. 1997. View Article : Google Scholar : PubMed/NCBI

Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI

Koliarakis I, Messaritakis I, Nikolouzakis TK, Hamilos G, Souglakos J and Tsiaoussis J: Oral Bacteria and Intestinal Dysbiosis in Colorectal Cancer. Int J Mol Sci. 20:41462019. View Article : Google Scholar :